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Introduction
Industrial biotechnology, also known as
white biotechnology, is considered to be a
revolutionary biotechnology field beside red
and green biotechnology. After red (medici-
ne) and green (agriculture), white biotech-
nology is now gaining momentum. With
numerous applications e.g. in biocatalysis
and fermentation technology, white biotech
companies are able to produce – often from
biomass out of agricultural products - bio-
based chemicals (like vitamins, amino acids
or enzymes for textile finishing and the
detergent industry), biomaterials (like bio-
degradable plastics for packaging or medical
applications) and biofuels. Biotechnological
syntheses are supposed to revolutionize
many classical chemical synthetic routes for
established chemicals and will outpace
those by higher cost-efficiency, saving feed-
stock and energy resources and offering
valuable benefits to the environment by
lower or even no greenhouse gas emissions.
The Capital Market's Perception
– White versus Red
Whereas Red Biotechnology is already
accepted by the capital markets and domi-
nates by far the total number of biotechno-
logy companies, there are only few dedica-
ted white biotech companies. Venture capi-
talists have preferred red opportunities,
while white biotechnology used to have a
lower attendance with capital markets and
is still more driven by big chemical corpora-
tions than an agile start-up scene. The focus
of red biotech is on new drugs with a relati-
vely easy to estimate market potential and
share, while industrial biotechnology main-
ly develops new process routes to already
known drugs or chemicals. These characte-
ristics require more knowledge of the indus-
try and often contribute to the lack of inves-
tors' attendance of white versus red biotech-
nology. In comparison to red, white biotech
processes or products usually serve a broa-
der range of applications and should thus
diversify the investor's risks accordingly.
However, many venture capitalists still are
not aware of the chances or even seem to
shy away from taking the white opportuni-
ty, presumably because of difficulties in rea-
sonably estimating the scope of market
potential and market share that could be
achieved with a single process or product.
However, the impact of white biotechnology
can be found in most future oriented state-
ments of big chemical companies and is
expected to drive future chemicals earnings
significantly. Furthermore, the number of
spin-offs from universities and start-ups
with a dedication on white biotech is
expected to pick up momentum. Investors
conferences are held with dedication on
white biotech companies and investors are
more and more looking for this emerging
sector. All this makes it obvious that now
could be the time to look for opportunities
for paying-off investments.
The adequate valuation of investment
opportunities in growth companies within
industrial biotechnology is, though, often
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seen as a challenge by market participants.
Principally, several techniques are available
for valuing white biotech companies: The
DCF method, the Multiples valuation, Ventu-
re Capital method, the Portfolio or Sum-Of-
The-Parts approach or option based valuati-
on techniques like the Real Option valuati-
on. Admittedly, it can be tricky to put a price
tag on biotechnology companies that often
offer little more than the promise of success
in the future. Just because someone in the
lab cries "Eureka!", that doesn't necessarily
mean that a revolutionary process or enzy-
me has been found. In the biotech sector, it
can take many years to determine whether
all the effort will translate into returns for a
company. Red biotechnology is a forward-
looking, cash-hungry industry. Sometimes, it
takes far beyond a billion of Euros and many
years to develop a drug which then might
not come to market. So biotech and pharma
companies are constantly looking to all
areas of the finance industry for funding.
Their assets are often highly intangible
(intellectual property) and, because they are
so forward-looking, there is little current
concrete information available for the inves-
tor other than retrospective insights into
previous projects. It is a high-risk business,
but one which can give massive returns. In
comparison to red, white biotech invest-
ments often afford lower initial investments
and offer lower risk due to a diversification
among applications and industries. Two of
the characteristics of white biotech, to
which investors are giving increasing atten-
tion, are the typically much shorter time
span from idea to market – 3 to 5 years, com-
pared to 10-12 years for a biomedical product
– and less regulatory requirements. The
accumulated market potential, market sha-
res and derived free cash flows are, however,
more complex compared to red biotech pro-
jects and can require the engagement of
several industry specialists. Industry teams
that are engaged in the valuation can com-
prise biotechnology specialist, chemicals
and consumer good or medical applications
expertise. Despite the complexity of deri-
ving a value from white biotechnology pro-
jects, the business models are often highly
promising and many white investment
opportunities, that are currently undiscover-
ed, wait to be caught. For picking the right
alternative, investors need to be able to eva-
luate such companies properly in order to
make proper business decisions about their
investment. The credit crunch increases the
need for the proper valuation approach in
general, but in particular for the high-risk
biotechnology sector: Due to the credit
crunch, the European Biopharmaceutical
Enterprises trade association reckons that
20% of all European biotech companies
could go out of business in the next six to 18
months (Warmington, 2009). Comparatively,
this could mean another chance for white
biotechnology to increase attention due to
eventually more stable business models and
broader application ranges.
A Glimpse into the Future of White
Biotechnology
Although reality could not come up with
the forecasted impacts of white biotech on
traditional chemical production processes, it
is more a question of when but if the revolu-
tion will happen (EuropaBio, 2003). The
development and use of Industrial Biotech-
nology is therefore essential to the future
competitiveness of European industry and
provides a sound technological base for the
sustainable society of the future.
In the long run, it is undoubted that an
increasing number of chemicals and materi-
als will be produced using biotechnology in
one or more of the processing steps. Biotech-
nological processes will be used to produce
chemicals and materials which are hard or
impossible to produce or – more frequently -
make existing products in a more efficient
way. Biotechnology will allow increasingly
eco-efficient use of renewable resources as
industrial raw materials. Rural bio-refineries
can replace port-based oil refineries where-
ver it is economically feasible. Industrial
biotechnology will enable a range of indus-
tries to manufacture products in an econo-
mically and environmentally sustainable
way.
Furthermore, biomass-derived energy
based on biotechnology is expected to
account for an increasing share of European
energy consumption. European industry
will be innovative and competitive, with
sustained cooperation and support between
the research community, industry, agricultu-
re and civil society. Green biotechnology
will make a substantial contribution to the
efficient production of biomass raw materi-
als and green and white biotechnology will
thus combine to an integrated value chain.
The prospects will, however, only become
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reality with the appropriate enabling politi-
cal and economical environment stimula-
ting research and innovation, entrepreneur-
ship, product approval and market develop-
ment. As long as the cost of fossil fuel and
feedstock for key chemicals have not passed
their respective critical thresholds, industri-
al biotechnology and its products will need
political support and funding, particularly
in the energy and bulk-chemicals sectors.
Other uses of industrial biotechnology,
however, such as biocatalytic conversions of
fine and specialty chemicals and the manu-
facture of high-value products, such as
nutraceuticals, cosmeceuticals and perfor-
mance chemicals offer dynamic growth
opportunities both for established chemical
industries, as well as emerging entrepreneu-
rial enterprises. Attracting venture capital
(VC) will remain a challenge in the short
and medium term particularly for white bio-
tech companies due to VC firms shying away
from cyclical businesses and risks that have
not been made transparent sufficiently by
the biotech's management. Furthermore, VC
firms need a vision on the appropriate exit
pathways. They often stay onboard for
about four to eight years and look for IPOs
or trade sale to big chemicals companies. In
comparison to the red alternative, there is
little evidence on the IPO or M&A history
with respect to industrial biotech targets.
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